ACLS Stock Analysis: Axcelis Technologies | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 4.441m USD | 12M Return: 92.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 122M
EPS Trend: -85.8%
Qual. Beats: 0
Rev. Trend: -86.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Axcelis Technologies (ACLS) is a U.S.-based manufacturer of ion implantation and related processing equipment used in semiconductor chip fabrication. The company supplies a range of high-energy, high-current, and medium-current implanters to chipmakers across North America, Europe, and Asia Pacific, selling primarily through a direct sales force.
In addition to new equipment, Axcelis generates recurring aftermarket revenue through spare parts, equipment upgrades, maintenance services, customer training, and the resale of used tools, a model common across the semiconductor equipment industry that helps smooth the cyclicality tied to fab capital spending. Founded in 1978 and headquartered in Beverly, Massachusetts, the company operates within the semiconductor materials and equipment sub-industry of the Information Technology sector.
- Ion implanter demand rises with memory chip capex recovery
- Aftermarket services revenue grows as installed base expands
- China semiconductor equipment sales face export control risks
| Net Income: 100.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -2.73 > 1.0 |
| NWC/Revenue: 86.55% < 20% (prev 95.36%; Δ -8.80% < -1%) |
| CFO/TA 0.07 > 3% & CFO 96.6m > Net Income 100.9m |
| Net Debt (-324.6m) to EBITDA (137.5m): -2.36 < 3 |
| Current Ratio: 4.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.0m) vs 12m ago -4.19% < -2% |
| Gross Margin: 43.61% > 18% (prev 44.61%; Δ -1.00% > 0.5%) |
| Asset Turnover: 62.28% > 50% (prev 71.46%; Δ -9.19% > 0%) |
| Interest Coverage Ratio: 22.65 > 6 (EBIT TTM 119.8m / Interest Expense TTM 5.29m) |
| A: 0.53 (Total Current Assets 935.7m - Total Current Liabilities 203.9m) / Total Assets 1.37b |
| B: 0.37 (Retained Earnings 512.8m / Total Assets 1.37b) |
| C: 0.09 (EBIT TTM 119.8m / Avg Total Assets 1.36b) |
| D: 3.17 (Book Value of Equity 1.04b / Total Liabilities 329.9m) |
| Altman-Z'' = 8.63 = AAA |
| DSRI: 1.11 (Receivables 161.8m/164.9m, Revenue 845.4m/958.1m) |
| GMI: 1.02 (GM 44.61% / 43.61%) |
| AQI: 2.63 (AQ_t 0.25 / AQ_t-1 0.09) |
| SGI: 0.88 (Revenue 845.4m / 958.1m) |
| TATA: 0.00 (NI 100.9m - CFO 96.6m) / TA 1.37b) |
| Beneish M = -2.03 (Cap -4..+1) = BB |
As of July 10, 2026, the stock is trading at USD 142.93 with a total of 388,147 shares traded. Over the past week, the price has changed by -19.85%, over one month by -13.15%, over three months by +32.05% and over the past year by +92.19%.
Current recommended Stop Loss: 124.90 (which is 12.6% or 1.3 ATR below the current price).
Axcelis Technologies has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold ACLS.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 169.7 | 18.7% |
P/E Trailing = 44.7368
P/E Forward = 47.3934
P/S = 5.2529
P/B = 5.2466
P/EG = 1.4493
Revenue TTM = 845.4m USD
EBIT TTM = 119.8m USD
EBITDA TTM = 137.5m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 1.65m USD (from shortTermDebt, last quarter)
Debt = 42.0m USD (from shortLongTermDebtTotal, last quarter) (leases 42.0m already included)
Net Debt = -324.6m USD (calculated: Debt 42.0m - CCE 366.6m)
Enterprise Value = 4.12b USD (4.44b + Debt 42.0m - CCE 366.6m)
Interest Coverage Ratio = 22.65 (Ebit TTM 119.8m / Interest Expense TTM 5.29m)
EV/FCF = 46.53x (Enterprise Value 4.12b / FCF TTM 88.5m)
FCF Yield = 2.15% (FCF TTM 88.5m / Enterprise Value 4.12b)
FCF Margin = 10.46% (FCF TTM 88.5m / Revenue TTM 845.4m)
Net Margin = 11.93% (Net Income TTM 100.9m / Revenue TTM 845.4m)
Gross Margin = 43.61% ((Revenue TTM 845.4m - Cost of Revenue TTM 476.8m) / Revenue TTM)
Gross Margin QoQ = 40.50% (prev 46.97%)
Tobins Q-Ratio = 2.99 (Enterprise Value 4.12b / Total Assets 1.37b)
Interest Expense / Debt = 12.60% (Interest Expense 5.29m / Debt 42.0m)
Taxrate = 12.88% (14.9m / 115.8m)
NOPAT = 104.3m (EBIT 119.8m * (1 - 12.88%))
Current Ratio = 4.59 (Total Current Assets 935.7m / Total Current Liabilities 203.9m)
Debt / Equity = 0.04 (Debt 42.0m / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = -2.36 (Net Debt -324.6m / EBITDA 137.5m)
Debt / FCF = -3.67 (Net Debt -324.6m / FCF TTM 88.5m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.43% (Net Income 100.9m / Total Assets 1.37b)
RoE = 9.79% (Net Income TTM 100.9m / Total Stockholder Equity 1.03b)
RoCE = 11.18% (EBIT 119.8m / Capital Employed (Equity 1.03b + L.T.Debt 40.8m))
RoIC = 9.23% (NOPAT 104.3m / Invested Capital 1.13b)
WACC = 13.93% (E(4.44b)/V(4.48b) * Re(13.96%) + D(42.0m)/V(4.48b) * Rd(12.60%) * (1-Tc(0.13)))
Discount Rate = 13.96% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -100.00 | Cagr: -2.81%
[DCF] Terminal Value 55.31% ; FCFF base≈102.2m ; Y1≈89.7m ; Y5≈72.4m
[DCF] Fair Price = 30.47 (EV 611.7m - Net Debt -324.6m = Equity 936.3m / Shares 30.7m; r=13.93% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -85.82 | EPS CAGR: -15.80% | SUE: 0.06 | # QB: 0
Revenue Correlation: -86.61 | Revenue CAGR: -10.65% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.89 | Chg30d=+0.00% | Revisions=+25% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.04 | Chg30d=+0.00% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=3.83 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=-21.4% | GrowthRev=+0.6%
EPS next Year (2027-12-31): EPS=4.85 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+26.5% | GrowthRev=+9.6%
[Analyst] Revisions Ratio: +0% (up=2, down=2)